Author: admin

Menkes Disease Market 2032: Epidemiology Review, Pipeline Breakthroughs, Regulatory Highlights by DelveInsight | CypriumTherapeutics and Sentynl Therapeutics

The Menkes Disease Market size was valued at USD 0.2 Million in the year 2021 and the report offers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the

The Menkes Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Menkes Disease pipeline products will significantly revolutionize the Menkes Disease market dynamics.  

 

DelveInsight’s “Menkes Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Menkes Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Menkes Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Menkes Disease Market Insights

 

Some of the key facts of the Menkes Disease Market Report: 

  • The Menkes Disease market size was valued at USD 0.2 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • National Organization for Rare Disorders (NORD) (n.d.) has defined Menkes syndrome as an inherited X-linked recessive disorder that affects many systems in the body

  • Among G11, the United States had 79 diagnosed prevalent cases of Menkes Disease in 2021

  • As per the assessment of DelveInsight, total diagnosed prevalent cases of Menkes Disease in the G11 were found to be 265 in 2021

  • Key Menkes Disease Companies: CypriumTherapeutics and Sentynl Therapeutics, and others

  • Key Menkes Disease Therapies: CUTX-101, and others

  • The Menkes Disease epidemiology based on gender analyzed that Menkes Disease usually affects male neonates through unaffected carrier women. It may occurs in females, related to unusual genetic circumstances

 

Menkes Disease Overview

Menkes disease (MD) is a lethal infantile neurodegenerative disorder with X-linked inheritance. It is an inherited X-linked recessive disorder caused by mutations in the ATP7A gene that is responsible for the transport of copper throughout the body. The mutation could lead to premature birth and may have non-specific symptoms such as hypothermia, hypoglycemia, and prolonged jaundice. These non-specific clinical and biochemical findings could result in the misdiagnosis of neonatal Menkes disease.

 

Get a Free sample for the Menkes Disease Market Report – 

https://www.delveinsight.com/sample-request/menkes-disease-market

 

Menkes Disease Market  

The dynamics of the Menkes Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Menkes Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Download the report to understand which factors are driving Menkes Disease epidemiology trends @ Menkes Disease Epidemiological Insights

 

Menkes Disease Epidemiology Segmentation:

The Menkes Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Menkes Disease

  • Prevalent Cases of Menkes Disease by severity

  • Gender-specific Prevalence of Menkes Disease

  • Diagnosed Cases of Episodic and Chronic Menkes Disease

 

Menkes Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Menkes Disease market or expected to get launched during the study period. The analysis covers Menkes Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Menkes Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Menkes Disease treatment, visit @ Menkes Disease Medications 

 

Menkes Disease Therapies and Key Companies

  • CUTX-101: CypriumTherapeutics and Sentynl Therapeutics

 

Menkes Disease Market Drivers

  • Submission of NDA of CUTX-101

  • Increasing awareness among families who have a history of Menkes

  • Parents of affected babies understand the rarity of the disease and allow their children to be a part of the trial

  • Ongoing development of screening techniques

  • Ongoing development of gene therapy

 

Menkes Disease Market Barriers

  • Clinical challenges in the early diagnosis of disease

  • Inability to trace the carrier mother

  • Insufficient number of studies to estimate the exact number of Menkes patients

  • Insufficient number of researches for the treatment of Menkes disease

 

Scope of the Menkes Disease Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Menkes Disease Companies: CypriumTherapeutics and Sentynl Therapeutics, and others

  • Key Menkes Disease Therapies: CUTX-101, and others

  • Menkes Disease Therapeutic Assessment: Menkes Disease current marketed and Menkes Disease emerging therapies

  • Menkes Disease Market Dynamics: Menkes Disease market drivers and Menkes Disease market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Menkes Disease Unmet Needs, KOL’s views, Analyst’s views, Menkes Disease Market Access and Reimbursement 

 

Discover more about therapies set to grab major Menkes Disease market share @ Menkes Disease market forecast

 

Table of Contents 

1. Menkes Disease Market Report Introduction

2. Executive Summary for Menkes Disease

3. SWOT analysis of Menkes Disease

4. Menkes Disease Patient Share (%) Overview at a Glance

5. Menkes Disease Market Overview at a Glance

6. Menkes Disease Disease Background and Overview

7. Menkes Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Menkes Disease 

9. Menkes Disease Current Treatment and Medical Practices

10. Menkes Disease Unmet Needs

11. Menkes Disease Emerging Therapies

12. Menkes Disease Market Outlook

13. Country-Wise Menkes Disease Market Analysis (2019–2032)

14. Menkes Disease Market Access and Reimbursement of Therapies

15. Menkes Disease Market Drivers

16. Menkes Disease Market Barriers

17.  Menkes Disease Appendix

18. Menkes Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Menkes Disease Market 2032: Epidemiology Review, Pipeline Breakthroughs, Regulatory Highlights by DelveInsight | CypriumTherapeutics and Sentynl Therapeutics

Slide into Summer with the Top 35 Most Iconic Songs of The Season, featuring Atlanta’s own Brett Ryder debuting his Hip-Hop Pop Single “Summer Breeze”

“Summer Breeze Brett Ryder Album Cover”
Get ready for the ultimate summer playlist! As temperatures rise and memories of carefree days beckon, immerse yourself in the 35 most iconic summer songs of all time. From classics like “Summertime” by DJ Jazzy Jeff & The Fresh Prince to modern hits like “Cruel Summer” by Taylor Swift, this playlist has it all. And introducing the newest addition, “Summer Breeze,” by 18-year-old Atlanta talent – singer/songwriter/multi-instrumentalist, Brett Ryder.

Atlanta, GA – May 14, 2024 – Summer has always been the season that inspires songwriters the most. While there are artists whose music embodies the feeling of autumn or winter, no musician has ever competed to create “the song of spring.” And it’s no surprise. Most music is ultimately about conveying a sense of freedom, and there’s no time of year that better represents that feeling than summer.

Even if you’re long past the days of having a “summer vacation,” there’s something about the warm temperatures, sprinklers on lawns, and backyard BBQ’s that can transport you back to being a carefree kid again. So slather on the SPF and dive into this collection of the 35 most iconic summer songs of all time. This list spans decades of summer jams, from ’60s soul sunshine to “Hot Girl Summer.” But first check out the newest song, Summer Breeze, by 18-year-old Atlanta-based singer/songwriter/multi-instrumentalist, Brett Ryder, who is making a name for himself in the music industry. Summer Breeze drops Friday, May 17th, 2024 everywhere you stream music!

To listen before anyone else – check out this link:

“Summer Breeze” captures the essence of everyone’s favorite season with a catchy hook, upbeat lyrics and an addictive beat, making it the perfect addition to any playlist. This feel-good track will have listeners craving the carefree days of summer lovin’, soaking up the sun, or drinking a margarita while lounging on a unicorn float. It doesn’t matter what kind of music you like, there’s something about this song that appeals to everyone. 

Now, on to the list:

The 35 Most Iconic Summer Songs of All Time:

  1. “Summertime” by DJ Jazzy Jeff & The Fresh Prince
  2. “California Gurls” by Katy Perry ft. Snoop Dogg
  3. “Hot Fun in the Summertime” by Sly & The Family Stone
  4. “Surfin’ U.S.A.” by The Beach Boys
  5. “In the Summertime” by Mungo Jerry
  6. “Cruel Summer” by Bananarama
  7. “Summer of ’69” by Bryan Adams
  8. “Good Vibrations” by The Beach Boys
  9. “School’s Out” by Alice Cooper
  10. “Boys of Summer” by Don Henley
  11. “Under the Boardwalk” by The Drifters
  12. “All Summer Long” by Kid Rock
  13. “Kokomo” by The Beach Boys
  14. “Summer Nights” by John Travolta & Olivia Newton-John
  15. “Surfin’ Safari” by The Beach Boys
  16. “Summertime Blues” by Eddie Cochran
  17. “Summer in the City” by The Lovin’ Spoonful
  18. “Walking on Sunshine” by Katrina and the Waves
  19. “Here Comes the Sun” by The Beatles
  20. “Rockaway Beach” by Ramones
  21. “Summer Love” by Justin Timberlake
  22. “Itsy Bitsy Teenie Weenie Yellow Polka Dot Bikini” by Brian Hyland
  23. “Summertime Sadness” by Lana Del Rey
  24. “Steal My Sunshine” by Len
  25. “Dancing in the Street” by Martha and the Vandellas
  26. “The Boys of Summer” by Ataris
  27. “Summer Wind” by Frank Sinatra
  28. “Heat Wave” by Martha and the Vandellas
  29. “Summer Nights” by Rascal Flatts
  30. “Wipe Out” by The Surfaris
  31. “Sittin’ on the Dock of the Bay” by Otis Redding
  32. “Soak Up the Sun” by Sheryl Crow
  33. “Summer Girls” by LFO
  34. “Cruel Summer” by Taylor Swift
  35. “The Tide is High” by Blondie

About Brett Ryder:

Hailing from Atlanta, Georgia, Brett Ryder is a singer-songwriter and multi-instrumentalist known for his soulful vocals, heartfelt lyrics, and infectious melodies. Drawing inspiration from classic rock to modern pop, Brett’s music is a unique blend of timeless charm and contemporary flair.

For more information about Brett Ryder and his music, visit www.brettryder.com

Media Contact
Company Name: Ryder Records, LLC
Contact Person: Laura Kronen
Email: Send Email
Phone: 9178614750
City: Atlanta
State: Georgia
Country: United States
Website: www.brettryder.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Slide into Summer with the Top 35 Most Iconic Songs of The Season, featuring Atlanta’s own Brett Ryder debuting his Hip-Hop Pop Single \”Summer Breeze\”

High-grade Glioma Market 2032: Epidemiology Trends, Innovative Therapies, Regulatory Approvals by DelveInsight | Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharma

The High-grade Glioma Market size was valued approximately USD 1.4 billion in 2022 and the report offers an in-depth understanding of the High-grade Glioma, historical and forecasted epidemiology as well as the High-grade Glioma market trends in the 7MM.

DelveInsight’s “High-grade Glioma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the High-grade Glioma, historical and forecasted epidemiology as well as the High-grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the High-grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; High-grade Glioma Market Forecast

 

Some of the key facts of the High-grade Glioma Market Report: 

  • The High-grade Glioma market size was valued approximately USD 1.4 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In November 2023, BioMimetix revealed that its BMX-001, when administered alongside radiotherapy and temozolomide, extended the median survival of glioma patients by 6.6 months. Moreover, this treatment combination mitigated radiation-induced cognitive impairments and enhanced the integrity of white matter. These outcomes stem from the Phase II study (NCT02655601) conducted by the clinical-stage biotech, focusing on evaluating the candidate in patients with high-grade glioma (HGG).

  • The collective number of new cases of high-grade glioma (HGG) in the seven main markets was approximately 35,000 in 2022, with expectations of a rise over the study duration.

  • Some of the most hopeful upcoming medications in the high-grade glioma (HGG) developmental pipeline include Eflornithine, Regorafenib, Ofranergene, Obadenovec, AV-GBM-1, Tasadenoturev, VAL-083, ONC201, Selinexor, VBI-1901, Paxalisib, MDNA55, ITI-1000, and the combination of INO-5401, INO-9012, and Cemiplimab.

  • Throughout the research period from 2019 to 2032, the United States holds the largest market share for high-grade glioma (HGG), surpassing the combined market sizes of the EU4 countries, the UK, and Japan. In 2022 alone, the market size in the United States was estimated to exceed USD 900 million.

  • Key High-grade Glioma Companies: Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharmaceuticals, Nationwide Children’s Hospital, Rigel Pharmaceuticals, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others

  • Key High-grade Glioma Therapies: Cerebraca wafer, BMX-001, ONC201, LAM561, Ribociclib, Olutasidenib + TMZ, Eflornithine + Lomustine, BMX-001, Regorafenib, Durvalumab (MEDI4736), Tasadenoturev (DNX-2401), ONC201, Berubicin, VBI-1901, Paxalisib (GDC-0084), AV-GBM-1, MDNA55, VAL-083 (Dianhydrogalactitol), Pomalidomide, LP561A1 (2-OHOA), ITI-1000 (pp65 DC Vaccine), INO-5401+ INO-9012+ Cemiplimab (REGN2810), and others

  • The High-grade Glioma epidemiology based on gender analyzed that High-grade Glioma is more common in men than in women

  • The High-grade Glioma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage High-grade Glioma pipeline products will significantly revolutionize the High-grade Glioma market dynamics.

 

High-grade Glioma Overview

High-grade glioma (HGG) refers to a group of aggressive brain tumors that arise from glial cells, which are supportive cells in the brain and spinal cord. These tumors are characterized by their rapid growth and tendency to invade surrounding brain tissue. High-grade gliomas are classified as grade III or grade IV tumors based on their histological features and aggressiveness.

 

Get a Free sample for the High-grade Glioma Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market

 

High-grade Glioma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

High-grade Glioma Epidemiology Segmentation:

The High-grade Glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of High-grade Glioma

  • Prevalent Cases of High-grade Glioma by severity

  • Gender-specific Prevalence of High-grade Glioma

  • Diagnosed Cases of Episodic and Chronic High-grade Glioma

 

Download the report to understand which factors are driving High-grade Glioma epidemiology trends @ High-grade Glioma Epidemiology Forecast

 

High-grade Glioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the High-grade Glioma market or expected to get launched during the study period. The analysis covers High-grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the High-grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

High-grade Glioma Therapies and Key Companies

  • Cerebraca wafer: Everfront Biotech Co., Ltd.

  • BMX-001: BioMimetix JV, LLC

  • ONC201: Chimerix

  • LAM561: Laminar Pharmaceuticals

  • Ribociclib: Nationwide Children’s Hospital

  • Olutasidenib + TMZ: Rigel Pharmaceuticals

  • Eflornithine + Lomustine: Orbus Therapeutics

  • BMX-001: BioMimetix

  • Regorafenib: Bayer

  • Durvalumab (MEDI4736): MedImmune

  • Tasadenoturev (DNX-2401): DNAtrix

  • ONC201: Chimerix

  • Berubicin: CNS Pharmaceuticals

  • VBI-1901: VBI Vaccines

  • Paxalisib (GDC-0084): Kazia Therapeutics

  • AV-GBM-1: Aivita Biomedical

  • MDNA55: Medicenna Therapeutics

  • VAL-083 (Dianhydrogalactitol): DelMar Pharmaceuticals

  • Pomalidomide: Bristol-Myers Squibb

  • LP561A1 (2-OHOA): Laminar Pharmaceuticals

  • ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

  • INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals

 

Discover more about therapies set to grab major High-grade Glioma market share @ High-grade Glioma Treatment Landscape

 

High-grade Glioma Market Strengths

  • Rise in HGG market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radio therapy techniques and novel systemic therapies.

  • Improvement in genomics and proteomics can lead to an acceleration in the discovery of novel treatment and drug deliverance.

 

High-grade Glioma Market Opportunities

  • Increasing incidence trend will provide better therapeutic approaches for the HGG market in the near future.

  • The market of High-grade Glioma is currently using Temozolomide and Evacizumab as approved therapies, but the market lacks an effective strategy to cure HGG, which provides a lucrative opportunity to develop more treatment options.

 

Scope of the High-grade Glioma Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key High-grade Glioma Companies: Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharmaceuticals, Nationwide Children’s Hospital, Rigel Pharmaceuticals, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others

  • Key High-grade Glioma Therapies: Cerebraca wafer, BMX-001, ONC201, LAM561, Ribociclib, Olutasidenib + TMZ, Eflornithine + Lomustine, BMX-001, Regorafenib, Durvalumab (MEDI4736), Tasadenoturev (DNX-2401), ONC201, Berubicin, VBI-1901, Paxalisib (GDC-0084), AV-GBM-1, MDNA55, VAL-083 (Dianhydrogalactitol), Pomalidomide, LP561A1 (2-OHOA), ITI-1000 (pp65 DC Vaccine), INO-5401+ INO-9012+ Cemiplimab (REGN2810), and others

  • High-grade Glioma Therapeutic Assessment: High-grade Glioma current marketed and High-grade Glioma emerging therapies

  • High-grade Glioma Market Dynamics: High-grade Glioma market drivers and High-grade Glioma market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • High-grade Glioma Unmet Needs, KOL’s views, Analyst’s views, High-grade Glioma Market Access and Reimbursement 

 

To know more about High-grade Glioma companies working in the treatment market, visit @ High-grade Glioma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. High-grade Glioma Market Report Introduction

2. Executive Summary for High-grade Glioma

3. SWOT analysis of High-grade Glioma

4. High-grade Glioma Patient Share (%) Overview at a Glance

5. High-grade Glioma Market Overview at a Glance

6. High-grade Glioma Disease Background and Overview

7. High-grade Glioma Epidemiology and Patient Population

8. Country-Specific Patient Population of High-grade Glioma 

9. High-grade Glioma Current Treatment and Medical Practices

10. High-grade Glioma Unmet Needs

11. High-grade Glioma Emerging Therapies

12. High-grade Glioma Market Outlook

13. Country-Wise High-grade Glioma Market Analysis (2019–2032)

14. High-grade Glioma Market Access and Reimbursement of Therapies

15. High-grade Glioma Market Drivers

16. High-grade Glioma Market Barriers

17.  High-grade Glioma Appendix

18. High-grade Glioma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: High-grade Glioma Market 2032: Epidemiology Trends, Innovative Therapies, Regulatory Approvals by DelveInsight | Everfront Biotech Co., Ltd., BioMimetix JV, LLC, Chimerix, Laminar Pharma

Diabetic Macular Edema Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Roche, Kodiak Science, Graybug Vision’s, Allergan, Inc., Quantel-Medical

The Diabetic Macular Edema Market size was valued approximately USD 2.9 Billion in the year 2022 and the report offers an in-depth understanding of the Diabetic Macular Edema, historical and forecasted epidemiology as well as the Diabetic Macular Edema market trends in the 7MM.

The Diabetic Macular Edema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Macular Edema pipeline products will significantly revolutionize the Diabetic Macular Edema market dynamics.  

 

DelveInsight’s “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diabetic Macular Edema, historical and forecasted epidemiology as well as the Diabetic Macular Edema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Diabetic Macular Edema market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Diabetic Macular Edema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Macular Edema Market Insights

 

Some of the key facts of the Diabetic Macular Edema Market Report: 

  • The Diabetic Macular Edema market size was valued approximately USD 2.9 Billion in the year 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • The diabetic macular edema (DME) market size for in the United States, as well as in the EU4 countries (Germany, Spain, Italy, France), the UK, and Japan collectively amounted to approximately USD 2,911 million in 2022.

  • As per DelveInsight’s assessment, the overall number of existing cases of diabetic macular edema (DME) in the seven major markets (7MM) was reported to be 1,073,892 in 2022, with projections indicating a notable compound annual growth rate (CAGR) over the course of the study period.

  • In 2022, the United States had the highest number of identified prevalent cases of diabetic macular edema (DME), estimated to be approximately 483,251. Projections suggest a substantial compound annual growth rate (CAGR) in these cases over time.

  • According to DelveInsight’s findings, the diagnosed prevalent cases of diabetic macular edema (DME) were classified into three age groups: 18-44 years, 45-64 years, and ≥75 years. In 2022, the highest number of cases, totaling 209,740, was observed in the age group of 45-64 years in the United States.

  • In 2022, 58% of cases of diabetic macular edema (DME) were reported in males, with females comprising 42% of cases across the seven major markets (7MM). Specifically in the United States, there were 280,286 cases among males and 202,966 cases among females in 2022. These figures are anticipated to increase during the forecast period from 2023 to 2034.

  • Key Diabetic Macular Edema Companies: EyePoint Pharmaceuticals, Inc., Ripple Therapeutics Pty Ltd, RemeGen Co., Ltd., Alimera Science, Laboratorios Sophia S.A, Oculis, Hoffmann-La Roche, Oxular Limited, Mabwell (Shanghai) Bioscience, Genentech, Inc., Hoffmann-La Roche, Allgenesis Biotherapeutics Inc., 4D Molecular Therapeutics, Kyowa Kirin, Inc., Incepta Pharmaceuticals Ltd, Ashvattha Therapeutics, Inc., and others

  • Key Diabetic Macular Edema Therapies: EYP-1901, IBE-814, RC-28E, Aflibercept, Bevacizumab, Dexamethasone ophthalmic suspension (OCS-01), Vamikibart, OXU-001, 9MW0813, Faricimab, Vamikibart, AG-73305, 4D-150 IVT, KHK4951, Ranibizumab, D-4517.2, and others

  • The Diabetic Macular Edema epidemiology based on gender analyzed that Diabetic Macular Edema is more prevalent in males as compared to females

 

Diabetic Macular Edema Overview

Diabetic macular edema (DME) is a complication of diabetes that affects the retina, the light-sensitive tissue at the back of the eye. It occurs when high blood sugar levels damage the small blood vessels in the retina, leading to swelling (edema) in the macula, the central part of the retina responsible for sharp, central vision.

 

Get a Free sample for the Diabetic Macular Edema Market Report:

https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market

 

Diabetic Macular Edema Market  

The dynamics of the Diabetic Macular Edema market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

 

Diabetic Macular Edema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Download the report to understand which factors are driving Diabetic Macular Edema epidemiology trends @ Diabetic Macular Edema Epidemiological Insights

 

Diabetic Macular Edema Epidemiology Segmentation:

The Diabetic Macular Edema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Diabetic Macular Edema

  • Prevalent Cases of Diabetic Macular Edema by severity

  • Gender-specific Prevalence of Diabetic Macular Edema

  • Diagnosed Cases of Episodic and Chronic Diabetic Macular Edema

 

Diabetic Macular Edema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Macular Edema market or expected to get launched during the study period. The analysis covers Diabetic Macular Edema market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Macular Edema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Diabetic Macular Edema treatment, visit @ Diabetic Macular Edema Medications

 

Diabetic Macular Edema Therapies and Key Companies

  • EYP-1901: EyePoint Pharmaceuticals, Inc.

  • IBE-814: Ripple Therapeutics Pty Ltd

  • RC-28E: RemeGen Co., Ltd.

  • Aflibercept: Alimera Science

  • Bevacizumab: Laboratorios Sophia S.A

  • Dexamethasone ophthalmic suspension (OCS-01): Oculis

  • Vamikibart: Hoffmann-La Roche

  • OXU-001: Oxular Limited

  • 9MW0813: Mabwell (Shanghai) Bioscience

  • Faricimab: Genentech, Inc.

  • Vamikibart: Hoffmann-La Roche

  • AG-73305: Allgenesis Biotherapeutics Inc.

  • 4D-150 IVT: 4D Molecular Therapeutics

  • KHK4951: Kyowa Kirin, Inc.

  • Ranibizumab: Incepta Pharmaceuticals Ltd

  • D-4517.2: Ashvattha Therapeutics, Inc.

 

Diabetic Macular Edema Market Strengths

  • Late-stage pipeline drugs such as Faricimab, Beovu and KSI-301 are some of the potential emerging therapies that have shown promising results and expected to improve the dosing interval

 

Diabetic Macular Edema Market Opportunities

  • Around in one-quarter or more of eyes with center-involving DME do not achieve complete resolution of the edema with anti-VEGF therapy and currently there is no curative treatment options for this refractory pool

 

Scope of the Diabetic Macular Edema Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Diabetic Macular Edema Companies: EyePoint Pharmaceuticals, Inc., Ripple Therapeutics Pty Ltd, RemeGen Co., Ltd., Alimera Science, Laboratorios Sophia S.A, Oculis, Hoffmann-La Roche, Oxular Limited, Mabwell (Shanghai) Bioscience, Genentech, Inc., Hoffmann-La Roche, Allgenesis Biotherapeutics Inc., 4D Molecular Therapeutics, Kyowa Kirin, Inc., Incepta Pharmaceuticals Ltd, Ashvattha Therapeutics, Inc., and others

  • Key Diabetic Macular Edema Therapies: EYP-1901, IBE-814, RC-28E, Aflibercept, Bevacizumab, Dexamethasone ophthalmic suspension (OCS-01), Vamikibart, OXU-001, 9MW0813, Faricimab, Vamikibart, AG-73305, 4D-150 IVT, KHK4951, Ranibizumab, D-4517.2, and others

  • Diabetic Macular Edema Therapeutic Assessment: Diabetic Macular Edema current marketed and Diabetic Macular Edema emerging therapies

  • Diabetic Macular Edema Market Dynamics: Diabetic Macular Edema market drivers and Diabetic Macular Edema market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Diabetic Macular Edema Unmet Needs, KOL’s views, Analyst’s views, Diabetic Macular Edema Market Access and Reimbursement 

 

Discover more about therapies set to grab major Diabetic Macular Edema market share @ Diabetic Macular Edema market forecast

 

Table of Contents 

1. Diabetic Macular Edema Market Report Introduction

2. Executive Summary for Diabetic Macular Edema

3. SWOT analysis of Diabetic Macular Edema

4. Diabetic Macular Edema Patient Share (%) Overview at a Glance

5. Diabetic Macular Edema Market Overview at a Glance

6. Diabetic Macular Edema Disease Background and Overview

7. Diabetic Macular Edema Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Macular Edema 

9. Diabetic Macular Edema Current Treatment and Medical Practices

10. Diabetic Macular Edema Unmet Needs

11. Diabetic Macular Edema Emerging Therapies

12. Diabetic Macular Edema Market Outlook

13. Country-Wise Diabetic Macular Edema Market Analysis (2019–2032)

14. Diabetic Macular Edema Market Access and Reimbursement of Therapies

15. Diabetic Macular Edema Market Drivers

16. Diabetic Macular Edema Market Barriers

17.  Diabetic Macular Edema Appendix

18. Diabetic Macular Edema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Macular Edema Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Roche, Kodiak Science, Graybug Vision’s, Allergan, Inc., Quantel-Medical

Optima Technologies Introduces Cybersecurity Courses to Empower Organizations and Individuals in the Digital Age

Optima Technologies Introduces Cybersecurity Courses to Empower Organizations and Individuals in the Digital Age

COPENHAGEN – May 14, 2024 – As the digital landscape continues to evolve, the importance of robust cybersecurity measures is of high importance and foremost priority.

In response to the growing demand for comprehensive cybersecurity training, Optima Technologies today announced the launch of a new suite of online courses: Cybersecurity 1, Cybersecurity 2,  Cybersecurity 3, and Bundle 1 + 2 + 3.

These courses are designed to cater to a diverse audience, ranging from top management to employees at all levels within organizations. They provide invaluable insights and practical knowledge to fortify cyber defenses and safeguard critical assets against ever-evolving threats.

The audience for these courses include C-suite executives, directors, and managers responsible for strategic decision-making and overseeing organizational security initiatives. System administrators, network engineers, and cybersecurity specialists tasked with implementing and maintaining security measures will find the courses to be useful for improving their professional capabilities. Professionals who are tasked with ensuring adherence to industry regulations and standards such as GDPR, HIPAA, and PCI DSS will benefit from the courses, as will entrepreneurs and small business owners seeking to protect their digital assets and customer data, software developers and programmers interested in integrating security best practices into their applications, analysts and consultants focused on identifying and mitigating cybersecurity risks within organizations, and individuals pursuing careers in cybersecurity or related fields, looking to acquire foundational knowledge and skills.

Optima Technologies’ Cybersecurity courses offer a comprehensive curriculum developed by industry experts. They cover essential topics tailored to address the diverse needs and skill levels of participants. Here’s why individuals and organizations should consider enrolling: 

  • Each course is meticulously crafted to provide practical insights and real-world scenarios, ensuring immediate applicability in professional settings.
  • With online delivery, participants have the flexibility to learn at their own pace, accommodating busy schedules without compromising the quality of education.
  • Led by seasoned cybersecurity professionals, the courses offer unparalleled expertise and guidance, enriching the learning experience and fostering skill development.
  • Engaging content, interactive quizzes, and hands-on exercises enhance retention and comprehension, making complex concepts accessible to learners of all backgrounds.
  • Upon successful completion, participants receive industry-recognized certification, validating their proficiency and enhancing career prospects in the competitive cybersecurity landscape.

Optima Technologies’ Cybersecurity courses stand out from traditional offerings due to several distinctive features:  

  • The tiered structure of Cybersecurity 1, 2, 3, and Bundle 1 + 2 + 3 facilitates a progressive learning journey, allowing participants to build upon foundational knowledge and advance their expertise incrementally.
  • The courses adopt a holistic approach to cybersecurity, addressing technical, operational, and human factors to provide a comprehensive understanding of threats and mitigation strategies.
  • Recognizing the diverse needs of learners, the courses offer multidimensional modules and topics, empowering individuals and organizations to tailor their learning experience to specific areas of interest or concern.
  • Beyond course completion, participants gain access to a community of peers and instructors, as well as ongoing resources and updates to stay abreast of emerging threats and industry trends.
  • Emphasizing hands-on learning and practical application, the courses equip participants with the skills and confidence to implement effective cybersecurity measures in their respective roles and environments.

Whether the prospective student is a seasoned cybersecurity professional looking to stay ahead of emerging threats or a newcomer seeking to enter this dynamic field, Optima Technologies’ Cybersecurity courses offer a gateway to knowledge, empowerment, and professional growth.

Optima Technologies has launched best-in-class cybersecurity online courses in 2024: 

  • Cybersecurity 1
  • Cybersecurity 2
  • Cybersecurity 3
  • Cybersecurity Bundle 1 + 2 + 3

Why participate in Optima Technologies’ cybersecurity online courses? All companies should focus more on protecting their assets and keeping criminal hackers away. Everyone in the organization must learn basic cybersecurity skills, and contribute to this protection.

If everyone is equipped with the same basic cybersecurity skills, then the organization will be sure to have a better understanding of developing and implementing a professional cybersecurity strategy.

It is important to work professionally with cybersecurity in the whole organization, so that all employees can contribute with cybersecurity and make the necessary actions that must be conducted to help to protect the assets of companies.

For further information and enrollment visit Optima Technologies’ website at:

https://optimatechnologiesglobal.com/academy/

About Optima Technologies

Optima Technologies is a global cybersecurity company committed to helping organizations worldwide optimize their cybersecurity. We work with customers across the private, public, and social sectors to solve complex cybersecurity challenges and protect their company assets. We combine coherent cybersecurity strategies and transformative technologies to help organizations optimize their cybersecurity performance. We want to build a strong brand in the cybersecurity industry worldwide. Our purpose is to help our customers to protect their assets from cyber criminals. We are the professionals in cybersecurity.

Media Contact
Company Name: Optima Technologies
Contact Person: Ib Knudsen
Email: Send Email
Phone: +[45] 27 83 23 20
Country: Denmark
Website: https://optimatechnologiesglobal.com/academy/

NeoRulerGO is Launching on Kickstarter on May 14th, 2024

In a groundbreaking development, NeoRulerGO has finally made its Kickstarter debut with an aim to revolutionize routine measurement chores at a time when accuracy and efficiency are critical. This portable, intelligent rolling ruler offers unmatched precision and adaptability in a small package by fusing state-of-the-art technology with intuitive features.

NeoRulerGO, which goes by the tagline “Carry Smaller, Measure Smarter,” is designed for people who need accuracy and mobility. The gadget itself, which fits neatly into pockets and provides measures with a precision of ±0.04inch(1mm), is a monument to creative engineering. The device is initially offered as part of the Kickstarter campaign for a special offer price of $49, which is $20 off lower than the $69.00 regular price. The complete package, which adds more accessories to improve functionality, is available for $99 (only 200 seats available), a $70 savings above its suggested retail price of $169.

A New Benchmark for Measuring Devices

NeoRulerGO is exceptionally user-friendly and versatile. It effortlessly switches between numerous measurements (mm, cm, inch, foot, yard, mile, km) and measures any surface, from simple straight lines to intricate curves, breaking the limitations of objects. With over ninety-three built-in scales and the option to customize scales on the fly, this device is ideal for everyone who needs a measure in daily life.

Intelligent Connectivity Functions

NeoRulerGO’s interaction with the MEAOZR app, which enables the rapid transfer and storing of measurement data, is one of its most notable features. Because of this intelligent connectivity, users can easily save and retrieve their measurements, which simplifies tasks and boosts output.

Designed with user efficiency and comfort in mind

The NeoRulerGO is made with user comfort in mind in addition to functionality. It comes with a NeoPencil case with an ergonomic design and movable grips for comfort. To ensure that it may be tailored to any work or preference, the kit also includes a variety of tip selections and a unique NeoPencil.

The NeoPencil is a lasting and multipurpose marking instrument with a body made of durable 7075 aluminum alloys and replaceable graphite nibs available in 12 other colors in addition to black. The NeoStand, which complements the NeoPencil, is a two-in-one tool that adds convenience and utility to the pencil’s elegant appearance. It securely holds the pencil in place and doubles as an eraser. When combined, these cutting-edge goods offer functionality and style, prolonging the useful life of conventional writing utensils.

Kickstarter Campaign Details

The Kickstarter campaign offers an early opportunity to acquire the NeoRulerGO at a significantly reduced price. Interested backers can visit the campaign page to learn more about the different packages available and secure their own NeoRulerGO before the special pricing expires.

Key links:

Kickstarter: https://www.kickstarter.com/projects/hozodesign/neorulergo-carry-smaller-measure-smarter 

Press Kit: https://drive.google.com/drive/folders/1dcVnI5Sa_zmMwAuvV72Hnol4WHQ6toVT?usp=sharing

Landing Page: https://hozodesign.com/pages/neoruler-go 

Media Contact
Company Name: HOZO DESIGN CO., Limited
Contact Person: Caroline
Email: Send Email
Country: China
Website: hozodesign.com/pages/neoruler-go

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NeoRulerGO is Launching on Kickstarter on May 14th, 2024

Inflammatory Myositis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | CSL Behring, Argenx, Priovant Therapeutics/Roivan

The Inflammatory Myositis Market size was valued approximately USD 575 million in 2022 and the report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the 7MM.

DelveInsight’s “Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Inflammatory Myositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Myositis Market Forecast

 

Some of the key facts of the Inflammatory Myositis Market Report: 

  • The Inflammatory Myositis market size was valued approximately USD 575 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In 2022, there were 184,204 confirmed cases of inflammatory myositis in the 7MM; by 2032, cases are predicted to rise at a 2.4% annual growth rate

  • Among the 7MM, the US had the most number of diagnosed prevalent cases of inflammatory myositis in 2022 (90,064), followed by the UK (68,079), EU4, Japan (26,060 cases), and other countries

  • In EU4 and the UK, there were 68,079 documented instances of inflammatory myositis in 2022. With 21,734 affected persons, Germany had the largest number of diagnosed prevalent cases, followed by Italy (14,776) and the UK (13,590). These cases are anticipated to rise in 2022 during the study period

  • Brepocitinib by Priovant Therapeutics/Roivant, Efgartigimod by Argenx, Hizentra developed by CSLBehring, and other potential Inflammatory Myositis therapies are anticipated to be launched within the projected period. These novel treatments show promise in the management of inflammatory myositis, and their introduction is anticipated to change the range of available treatments in the anticipated time frame.

  • Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others

  • Key Inflammatory Myositis Therapies: Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others

  • The Inflammatory Myositis epidemiology based on gender analyzed that females are more susceptible to suffer from Inflammatory myositis when compared to the male population, in the 7MM

  • The Inflammatory Myositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Myositis pipeline products will significantly revolutionize the Inflammatory Myositis market dynamics.

 

Inflammatory Myositis Overview

Inflammatory myositis is a group of rare autoimmune disorders characterized by inflammation and weakness of the muscles. These conditions involve inflammation of the muscles (myositis), leading to muscle weakness, pain, and fatigue. There are several types of inflammatory myositis, including polymyositis, dermatomyositis, and inclusion body myositis, each with its own specific features and patterns of muscle involvement.

 

Get a Free sample for the Inflammatory Myositis Market Report:

https://www.delveinsight.com/report-store/inflammatory-myositis-im-market

 

Inflammatory Myositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Inflammatory Myositis Epidemiology Segmentation:

The Inflammatory Myositis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Inflammatory Myositis

  • Prevalent Cases of Inflammatory Myositis by severity

  • Gender-specific Prevalence of Inflammatory Myositis

  • Diagnosed Cases of Episodic and Chronic Inflammatory Myositis

 

Download the report to understand which factors are driving Inflammatory Myositis epidemiology trends @ Inflammatory Myositis Epidemiology Forecast

 

Inflammatory Myositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Myositis market or expected to get launched during the study period. The analysis covers Inflammatory Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Inflammatory Myositis Therapies and Key Companies

  • Hizentra: CSL Behring

  • Efgartigimod: Argenx

  • Brepocitinib: Priovant Therapeutics/Roivant

  • Ultomiris: Alexion Pharmaceuticals

  • PF-06823859: Pfizer

  • Daxdilimab: Horizon Therapeutics

  • Baricitinib: Eli Lilly and Company

  • Nipocalimab: Janssen Research & Development

  • PF-06823859: Pfizer

  • Froniglutide: Immunoforge Co. Ltd.

  • Infliximab: Schering-Plough

  • Lovaza: GlaxoSmithKline

  • Rituximab: Roche Pharma AG

 

Discover more about therapies set to grab major Inflammatory Myositis market share @ Inflammatory Myositis Treatment Market

 

Inflammatory Myositis Market Strengths

  • The therapeutic landscape is prolific in determining the efficacy, safety, and tolerability of novel drugs in patients with IM and its various types.

 

Inflammatory Myositis Market Opportunities

  • The rising data on overall Inflammatory Myositis prevalence and its subtypes is expected to add significantly to the patient pool.

 

Scope of the Inflammatory Myositis Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others

  • Key Inflammatory Myositis Therapies: Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others

  • Inflammatory Myositis Therapeutic Assessment: Inflammatory Myositis current marketed and Inflammatory Myositis emerging therapies

  • Inflammatory Myositis Market Dynamics: Inflammatory Myositis market drivers and Inflammatory Myositis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Inflammatory Myositis Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Myositis Market Access and Reimbursement 

 

To know more about Inflammatory Myositis companies working in the treatment market, visit @ Inflammatory Myositis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Inflammatory Myositis Market Report Introduction

2. Executive Summary for Inflammatory Myositis

3. SWOT analysis of Inflammatory Myositis

4. Inflammatory Myositis Patient Share (%) Overview at a Glance

5. Inflammatory Myositis Market Overview at a Glance

6. Inflammatory Myositis Disease Background and Overview

7. Inflammatory Myositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Myositis 

9. Inflammatory Myositis Current Treatment and Medical Practices

10. Inflammatory Myositis Unmet Needs

11. Inflammatory Myositis Emerging Therapies

12. Inflammatory Myositis Market Outlook

13. Country-Wise Inflammatory Myositis Market Analysis (2019–2032)

14. Inflammatory Myositis Market Access and Reimbursement of Therapies

15. Inflammatory Myositis Market Drivers

16. Inflammatory Myositis Market Barriers

17.  Inflammatory Myositis Appendix

18. Inflammatory Myositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Myositis Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | CSL Behring, Argenx, Priovant Therapeutics/Roivan

Seratoptical Revolutions Skin Care Products placed in Famed Summer Beauty Box FabFitFun with over 2 Million Subscribers Recommendations from High Profile Celebrities, Influencers & Top Medical: AVRW

Avenir Wellness Solutions™ ($AVRW) Skin Care and Nutraceutical Products are Sold at Top Retailers Including Walmart ($WMT), Target ($TGT), CVS Health ($CVS), and Amazon ($AMZN)

Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.  

Company Currently Holds 15 Patents.  

Seratopical Revolution Skin Care Personally Used and Endorsed by Global Brand Ambassador & Strategic Partner Nicole Kidman and Other Major Celebrities. 

LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting All Seratopical Revolution Plant Based Products, Backed by Science with New “Ask the Expert” Videos, Answering Questions Directly from Customers.  

New Media Exposure on Strongly Followed Beauty Box Fab Fit Fun. 

Media Exposure in Top-Tier Publications Including CNN Underscored, Page Six, PEOPLE Magazine and More. 

Planned Series of Announcements to Cover New Developments for 2024.  

Avenir Wellness (OTCQB: AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems. The technology, which is based on 15 current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. As a vertically integrated platform company, Avenir Wellness (AVRW) looks to partner or license its IP technology with wellness companies worldwide.

Sera Labs, a wholly owned subsidiary of Avenir Wellness (AVRW), creates high-quality products that use science-backed, proprietary formulations. Products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Avenir Wellness (AVRW) Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including opt-in subscriptions, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers including Walmart, CVS and Target as well as on the Amzon.com platform.  

Famed Beauty Box Fab Fit Fun is also now starting to feature strong sales positioning for the Avenir Wellness (AVRW) Seratopical Revolutions line, further supported by new Instagram listings as can be seen here: https://www.instagram.com/p/C6t2fqeROlm/.   

Avenir Wellness (AVRW) has a current focus on the beauty and wellness markets which are growing at rapid rates. The global wellness sector, despite the pandemic, saw exponential growth in 2021 with a market size of $1.5 trillion, according to McKinsey. There is a strong overall and growing demand for supplements and nutraceuticals, a $587.3 billion market, according to the 2021 Grandview report. The beauty and personal care industry is a $534 billion market now and is set to grow 5.87% year over year according to Terakeet’s 2021 Beauty Industry Report. 

Nicole Kidman, After Discovering Seratopical Revolution On Her Own, is the Global Brand Ambassador of Avenir Wellness Because it is the Very Best Option

Avenir Wellness (AVRW) is represented by the famous Nicole Kidman as a Strategic Partner and Global Brand Ambassador.  

The story of Nicole Kidman’s involvement with Avenir Wellness (AVRW) is detailed on the Company’s website here: https://www.seralabshealth.com/pages/about and is also described in a direct interview with Avenir Wellness (AVRW) CEO Nancy Duitch on the well followed “New to the Street” Investment program. The interview can be watched at this link: https://www.youtube.com/watch?v=LuBto12YZmc. 

Avenir Wellness (AVRW) continues to receive high profile media attention with exposure for the company’s Seratopical Revolution product line. Avenir Wellness (AVRW) was able to secure coverage in top-tier publications, including CNN Underscored, Page Six, PEOPLE Magazine and more. These placements garnered over 513M media impressions for the increasingly popular and successful Avenir Wellness (AVRW) Seratopical Revolution brand.  

Some examples of the latest Avenir Wellness (AVRW) media exposure may be seen at the following links:  

SeratopicalRevolution_CNNUnderscored_8.30.23 1.pdf

SeratopicaRevolution_People_8.30.23 1.pdf

Image 9-1-23 at 2.14 PM (1) 1.jpeg

Seratopical_WholeFoodsMag_8.24.23 1.pdf

2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky

On February 13th Avenir Wellness (AVRW) issued a Letter to Shareholders from CEO Nancy Duitch which contained the following information: 

The Avenir Wellness (AVRW) team has been working diligently to expand marketing plans for 2024 and beyond. Current plans continue to include support from our Global Brand Ambassador Nicole Kidman as well as renowned plastic surgeon Dr. Michael A. Persky, M.D., F.A.C.S..

Nicole Kidman, who personally entrusts her own skin care to the Seratopical brand products, will continue to be an integral part of Avenir Wellness (AVRW) advertising campaigns through the use of her images and commentary as will Dr. Persky who joined the Avenir Wellness (AVRW) team in September. Dr. Persky will be expanding his support of brand marketing, social media, and advertising campaigns for the patent-pending DNA (Deep Nano Actives) Complex an instant anti-aging skin tightening serum that due to the cutting-edge peptide technology developed exclusively for Avenir Wellness (AVRW) allows the ingredients to penetrate to the dermal layers of the skin. Dr. Persky will also advise along with Rob Davidson on formulating the brand’s future plant-based, cruelty-free and scientifically grounded products and will continue to add credibility to the product line with his “Ask the Expert” video segments answering consumer questions. In his video segments, which have been very successful thus far and are being used on all social media platforms, Dr. Persky explains in detail why he loves the results and usefulness of the new Avenir Wellness (AVRW) Seratopical DNA Complex.

Link to Dr. Persky Videos

The Avenir Wellness (AVRW) Seratopical Revolution DNA Complex retails for $99.99 and is currently available for purchase at: https://seralabshealth.com/pages/introducing-dna-complex

Another exciting component of the Avenir Wellness (AVRW) expanding marketing plans in 2024 will be the launch of a new TikTok Shop to create an additional sales pipeline and boost brand awareness to a broader consumer base.

Overall, Avenir Wellness (AVRW) has never been in a better position to capitalize on the high intrinsic value of its unique and proprietary skin care formulations. With 15 patents under Avenir Wellness (AVRW) control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for Avenir Wellness (AVRW). 

The company plans to file its audited 2023 Annual Report shortly. Afterwards, Avenir Wellness (AVRW) management intends begin a new round of announcements to detail its 2024 developments including the latest details on strong product sales already taking place and projected to grow throughout the balance of the year and beyond.   

 

 

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Avenir Wellness Solutions, Inc.
Contact Person: Nancy Duitch, CEO
Email: Send Email
Phone: (760) 564-7400
Address:5805 Sepulveda Blvd #801
City: Sherman Oaks
State: California 91411
Country: United States
Website: https://www.avenirwellness.com/

Acute Pain Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Pfizer, Pharmbio Korea Co., Ltd., Xgene Pharma, Mylan Specialty, Allay Therapeutics

Within the 7MM countries the Acute Pain market size is anticipated to grow rapidly with a significant CAGR during the study period (2020-2034).

The Acute Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Pain pipeline products will significantly revolutionize the Acute Pain market dynamics.  

 

The Acute Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Acute Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Pain Market Insights

 

Some of the key facts of the Acute Pain Market Report: 

  • The Acute Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034) 

  • In 2021, the overall market size for acute pain in the United States was approximately USD 3 billion, and it is anticipated to increase throughout the research duration spanning from 2020 to 2034.

  • In January 2024, Vertex Pharmaceuticals reported encouraging outcomes from its Phase III initiative evaluating VX-548, a selective NaV1.8 inhibitor, for managing moderate-to-severe acute pain. This Phase III program encompassed two pivotal trials conducted post abdominoplasty and bunionectomy surgeries, respectively, both designed as randomized, double-blind, placebo-controlled studies. Additionally, a safety and efficacy investigation, devoid of a placebo group, included patients with diverse surgical and non-surgical pain conditions.

  • In 2023, there were approximately 42 million instances of postoperative pain cases in the United States, with trauma pain and acute medical illness following closely behind. These numbers are projected to rise by 2034.

  • DelveInsight’s projections indicate that in 2023, the United States saw approximately 36 million mild cases, around 45 million moderate cases, and about 15 million severe cases. These numbers are anticipated to climb throughout the study period from 2020 to 2034.

  • In 2023, close to 80 million instances of treated acute pain were identified in the United States. Projections suggest that these numbers will rise during the forecast period from 2024 to 2034.

  • Key Acute Pain Companies: Pharmbio Korea Co., Ltd., Xgene Pharmaceutical, Mylan Specialty, Allay Therapeutics, Inc., Johnson & Johnson, RDC Clinical Pty Ltd, Halia Therapeutics, Inc., Cessatech A/S, Primus Pharmaceuticals, Olatec Therapeutics LLC, Jiangsu HengRui Medicine, Pfizer, and others

  • Key Acute Pain Therapies: PBK_L1704 0.35mg, XG005 tablet, MR-107A-02, ATX-101, Acetaminophen/Naproxen Sodium Fixed Combination, Levagen+, HT-6184, CT001, Metaxalone 640 mg Oral Tablet, Dapansutrile, Bupivacaine Liposome Injection, Zavegepant, and others 

  • The Acute Pain epidemiology based on gender analyzed that, it can be concluded that there is no significant difference in occurrence of acute pain among male and female population

 

Acute Pain Overview

Acute pain is a type of pain that typically begins suddenly and is usually short-lived. It serves as a protective mechanism, alerting the body to potential injury or tissue damage. Acute pain can result from various causes, such as injury, surgery, or medical conditions like infections or inflammation. It is often described as sharp, intense, and localized to a specific area of the body.

 

Get a Free sample for the Acute Pain Market Report:

https://www.delveinsight.com/report-store/acute-pain-market

 

Acute Pain Market  

The dynamics of the Acute Pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034. 

“Of the emerging therapies, one of the most anticipated product to get launched is CL-108. Apart from this, several other molecules are in mid to late stage.”

 

Acute Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Download the report to understand which factors are driving Acute Pain epidemiology trends @ Acute Pain Epidemiological Insights

 

Acute Pain Epidemiology Segmentation:

The Acute Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Acute Pain

  • Prevalent Cases of Acute Pain by severity

  • Gender-specific Prevalence of Acute Pain

  • Diagnosed Cases of Episodic and Chronic Acute Pain

 

Acute Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Pain market or expected to get launched during the study period. The analysis covers Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Acute Pain treatment, visit @ Acute Pain Medications

 

Acute Pain Therapies and Key Companies

  • PBK_L1704 0.35mg: Pharmbio Korea Co., Ltd.

  • XG005 tablet: Xgene Pharmaceutical

  • MR-107A-02: Mylan Specialty, L

  • ATX-101: Allay Therapeutics, Inc.

  • Acetaminophen/Naproxen Sodium Fixed Combination: Johnson & Johnson

  • Levagen+: RDC Clinical Pty Ltd

  • HT-6184: Halia Therapeutics, Inc.

  • CT001: Cessatech A/S

  • Metaxalone 640 mg Oral Tablet: Primus Pharmaceuticals

  • Dapansutrile: Olatec Therapeutics LLC

  • Bupivacaine Liposome Injection: Jiangsu HengRui Medicine

  • Zavegepant: Pfizer

 

Acute Pain Strengths

  • Growing research and development is increasing the demand for better diagnosis and treatment options for acute pain. 

  • Recently, drugs with novel mechanisms of action and combinations are being investigated to overcome the challenges of this entity. 

  • Rising awareness about multimodal analgesia among clinicians and patient.

 

Acute Pain Opportunities

  • The market needs new therapy with superior efficacy as strong as opioids, but fewer side effect and drug dependency. 

  • Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market.

 

Scope of the Acute Pain Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Acute Pain Companies: Pharmbio Korea Co., Ltd., Xgene Pharmaceutical, Mylan Specialty, Allay Therapeutics, Inc., Johnson & Johnson, RDC Clinical Pty Ltd, Halia Therapeutics, Inc., Cessatech A/S, Primus Pharmaceuticals, Olatec Therapeutics LLC, Jiangsu HengRui Medicine, Pfizer, and others

  • Key Acute Pain Therapies: PBK_L1704 0.35mg, XG005 tablet, MR-107A-02, ATX-101, Acetaminophen/Naproxen Sodium Fixed Combination, Levagen+, HT-6184, CT001, Metaxalone 640 mg Oral Tablet, Dapansutrile, Bupivacaine Liposome Injection, Zavegepant, and others

  • Acute Pain Therapeutic Assessment: Acute Pain current marketed and Acute Pain emerging therapies

  • Acute Pain Market Dynamics: Acute Pain market drivers and Acute Pain market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Acute Pain Unmet Needs, KOL’s views, Analyst’s views, Acute Pain Market Access and Reimbursement 

 

Discover more about therapies set to grab major Acute Pain market share @ Acute Pain market forecast

 

Table of Contents 

1. Acute Pain Market Report Introduction

2. Executive Summary for Acute Pain

3. SWOT analysis of Acute Pain

4. Acute Pain Patient Share (%) Overview at a Glance

5. Acute Pain Market Overview at a Glance

6. Acute Pain Disease Background and Overview

7. Acute Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Pain 

9. Acute Pain Current Treatment and Medical Practices

10. Acute Pain Unmet Needs

11. Acute Pain Emerging Therapies

12. Acute Pain Market Outlook

13. Country-Wise Acute Pain Market Analysis (2020–2034)

14. Acute Pain Market Access and Reimbursement of Therapies

15. Acute Pain Market Drivers

16. Acute Pain Market Barriers

17.  Acute Pain Appendix

18. Acute Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Pain Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Pfizer, Pharmbio Korea Co., Ltd., Xgene Pharma, Mylan Specialty, Allay Therapeutics

Award-Winning Debut Poetry Collection “Shmehara” Receives Literary Titan Gold Book Award

Award-Winning Debut Poetry Collection "Shmehara" Receives Literary Titan Gold Book Award
Andi Kopek’s debut poetry collection, “Shmehara,” has been awarded the Literary Titan Gold Book Award, celebrating its innovative blend of poetry and visual art that addresses profound human experiences and emotions. The collection features 21 poems, each accompanied by dynamic illustrations and QR codes that enhance the reader’s engagement while exploring themes of resilience, compassion, and the human spirit amid conflict.

Nashville, TN – Andi Kopek’s groundbreaking debut poetry collection, “Shmehara,” has been honored with the esteemed Literary Titan Gold Book Award, recognizing outstanding literature.

“Shmehara” transcends traditional literary boundaries by integrating 21 evocative poems with immersive illustrations and QR code technology, allowing readers to engage with animated content that brings the text to life. Each poem, coupled with its dynamic illustration and insightful notes from both the author and illustrator, delves deeply into themes such as resilience, compassion, and the human spirit amid adversity.

The book reflects on a spectrum of human emotions and experiences, including childhood trauma, mental health, identity, love, and death, all while engaging with the overarching context of the Russian-Ukrainian conflict. Yet, its themes resonate universally, tapping into the core of the human experience. A notable aspect of the collection is its Foreword by Steven Komarnyckyj, a distinguished British-Ukrainian writer and translator, who lends his voice to underscore the significance of Kopek’s work in today’s cultural and historical context.

Literary Titan lauds “Shmehara” as a “poignant exploration of human emotions,” highlighting how Kopek skillfully blends poetry with visual art, enhancing the reader’s experience. The review further emphasizes the collection’s balance between acknowledging harsh realities and nurturing hope, making it a compelling read for those moved by the complexities of human experiences during times of conflict.

“Shmehara” is available now at andikopekart.ink, and 10% of its sales are donated to support Ukrainian children refugees through a humanitarian organization. Join Andi Kopek on this extraordinary literary and artistic journey, and immerse yourself in “Shmehara”—a testament to the enduring power of art in illuminating the human experience and inspiring positive change.

About the Book

Embark on an evocative journey through a collection of poetry that transcends traditional boundaries of the written word. This debut work combines lyrical verses with stunning illustrations and interactive QR codes, offering a multi-sensory exploration of resilience, compassion, and the indomitable human spirit. Each poem delves into the depths of personal and collective experience—from childhood trauma to the echoes of war—inviting readers to reflect on life’s complex emotions and the power of art to heal and inspire.

About the Author

Andi Kopek (Nashville, TN) is an award-winning poet, author, human rights advocate, and multi-media artist whose work is deeply rooted in resilience, compassion, and hope. With training in the medical field, neuroscience, behavior change, and coaching, Kopek has fully dedicated himself to art as a means of storytelling and healing.

Media Contact
Company Name: Literary Titan
Contact Person: Andi Kopek
Email: Send Email
Country: United States
Website: https://www.andikopekart.ink/